Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01266603 · ClinicalTrials.gov registry record · Phase 2
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT01266603: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01266603 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01266603, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if high-dose interleukin-2 (HDIL-2), when given in combination with recMAGE-A3 + AS15 ASCI (Antigen-Specific Cancer Immunotherapeutic), can help to control unresectable or metastatic melanoma in patients whose tumor tissue has the MAGE-A3 protein. The safety of this drug combination will also be studied. Researchers will also use samples of the original tumor or metastatic tissue (for example, lymph nodes or liver or lung) that are collected during screening to study if response to the study drug is related to the genes in the tissue.
Interventions
- DRUG HDIL-2
- BIOLOGICAL recMAGE-A3 + AS15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2011-02-22 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01266603
The ClinicalTrials.gov registry entry for NCT01266603 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HDIL-2 is the first listed.
NCT01266603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01266603 about?
NCT01266603 is a clinical study titled "High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI". The goal of this clinical research study is to learn if high-dose interleukin-2 (HDIL-2), when given in combination with recMAGE-A3 + AS15 ASCI (Antigen-Specific Cancer Immunotherapeutic), can help to control unresectable or metastatic melanoma in patients whose tumor tissue has the MAGE-A3 protein....
What is the current status of trial NCT01266603?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2011-02-22. Estimated completion is 2018-11-01.
What interventions are being tested in trial NCT01266603?
The interventions under investigation include: HDIL-2 (DRUG), recMAGE-A3 + AS15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01266603?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.